Delcath Systems, Inc. (NASDAQ:DCTH) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Delcath Systems, Inc. has received a consensus rating of "Moderate Buy" from analysts, with a target price averaging $24.50 per share.
• The stock recently traded up 4.2%, reaching $11.10, with significant trading volume of 626,157 shares.
• In its latest quarterly earnings report, Delcath Systems exceeded expectations by reporting $0.07 earnings per share on revenue of $24.16 million.

Shares of Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $24.50.

Several equities research analysts have recently weighed in on the company. HC Wainwright raised their price objective on Delcath Systems from $29.00 to $31.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th. Wall Street Zen lowered Delcath Systems from a "buy" rating to a "hold" rating in a research report on Sunday, August 10th. Stephens reissued an "overweight" rating and issued a $25.00 price target on shares of Delcath Systems in a research note on Monday, June 23rd. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Delcath Systems in a research note on Saturday, September 27th.

Delcath Systems Trading Up 4.2%

NASDAQ:DCTH traded up $0.45 during mid-day trading on Friday, reaching $11.10. 626,157 shares of the stock were exchanged, compared to its average volume of 665,612. The business has a fifty day moving average price of $10.92 and a 200 day moving average price of $12.58. Delcath Systems has a 1-year low of $8.08 and a 1-year high of $18.23. The firm has a market capitalization of $388.28 million, a PE ratio of 222.00 and a beta of 0.84.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.05. The company had revenue of $24.16 million during the quarter, compared to analyst estimates of $22.84 million. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. On average, sell-side analysts forecast that Delcath Systems will post -0.79 earnings per share for the current year.

Institutional Trading of Delcath Systems

Hedge funds have recently made changes to their positions in the stock. Palisades Investment Partners LLC boosted its holdings in shares of Delcath Systems by 58.0% during the second quarter. Palisades Investment Partners LLC now owns 270,310 shares of the company's stock worth $3,676,000 after purchasing an additional 99,226 shares during the period. Vanguard Group Inc. boosted its stake in shares of Delcath Systems by 13.8% during the 1st quarter. Vanguard Group Inc. now owns 1,394,028 shares of the company's stock valued at $17,746,000 after buying an additional 169,260 shares during the period. Principal Financial Group Inc. increased its position in Delcath Systems by 2.1% in the 1st quarter. Principal Financial Group Inc. now owns 117,620 shares of the company's stock worth $1,497,000 after purchasing an additional 2,437 shares during the last quarter. Bank of America Corp DE increased its holdings in Delcath Systems by 1,816.5% in the fourth quarter. Bank of America Corp DE now owns 25,700 shares of the company's stock worth $309,000 after buying an additional 24,359 shares during the last quarter. Finally, Invesco Ltd. acquired a new stake in Delcath Systems in the first quarter valued at approximately $5,084,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.